Divergent patterns of telomere maintenance mechanisms among human sarcomas: Sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas

Genes Chromosomes and Cancer

Volumn 41, Issue 2, 2004, Pages 155-162

  Ulaner, Gary A ^a,c   Hoffman, Andrew R ^a   Otero, Jesse ^a   Huang, Hsuan Ying ^b,d   Zhao, Zhiquan ^b   Mazumdar, Madhu ^b   Gorlick, Richard ^b   Meyers, Paul ^b   Healey, John H ^b   Ladanyi, Marc ^b  

^a STANFORD UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; ENZYME ACTIVITY; EWING SARCOMA; FEMALE; GENE; HTERT GENE; HUMAN; HUMAN TISSUE; MALE; OSTEOSARCOMA; POINT MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TELOMERE; TP53 GENE;

ACTINS; ADOLESCENT; ADULT; BASE SEQUENCE; BONE NEOPLASMS; CELL LINE, TUMOR; CHILD, PRESCHOOL; DNA PRIMERS; FEMALE; HUMANS; INFANT; MALE; OSTEOSARCOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA; SARCOMA, EWING'S; TELOMERASE; TELOMERE;

EID: 4143069054     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20074     Document Type: Article

References (42)

1. Barr FG. 1998. Translocations, cancer and the puzzle of specificity. Nat Genet 19:121-124.
2. Borden EC, Baker LH, Bell RS, Bramwell V, Demetri GD, Eisenberg BL, Fletcher CD, Fletcher JA, Ladanyi M, Meltzer P, O'Sullivan B, Parkinson DR, Pisters PW, Saxman S, Singer S, Sundaram M, Van Oosterom AT, Verweij J, Waalen J, Weiss SW, Brennan MF. 2003. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res 9:1941-1956.
3. Colgin LM, Baran K, Baumann P, Cech TR, Reddel RR. 2003. Human POT1 facilitates telomere elongation by telomerase. Curr Biol 13:942-946.
4. Dauphinot L, De Oliveira C, Melot T, Sevenet N, Thomas V, Weissman BE, Delattre O. 2001. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression. Oncogene 20:3258-3265.
5. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G, Aurias A, Thomas G. 1992. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359:162-165.
6. Fukuma M, Okita H, Hata J, Umezawa A. 2003. Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma. Oncogene 22:1-9.
7. Gisselsson D. 2002. Tumour morphology-interplay between chromosome aberrations and founder cell differentiation. Histol Histopathol 17:1207-1212.
8. Gisselsson D, Pettersson L, Hoglund M, Heidenblad M, Gorunova L, Wiegant J, Mertens F, Dal Cin P, Mitelman F, Mandahl N. 2000. Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity. Proc Natl Acad Sci USA 97:5357-5362.
9. Goytisolo FA, Samper E, Martin-Caballero J, Finnon P, Herrera E, Flores JM, Bouffler SD, Blasco MA. 2000. Short telomeres result in organismal hypersensitivity to ionizing radiation in mammals. J Exp Med 192:1625-1636.
10. Greaves M. 1996. Is telomerase activity in cancer due to selection of stem cells and differentiation arrest? Trends Genet 12:127-128.
11. Greenberg RA, O'Hagan RC, Deng H, Xiao Q, Hann SR, Adams RR, Lichtsteiner S, Chin L, Morin GB, DePinho RA. 1999. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 18:1219-1226.
12. Guilleret I, Yan P, Guillou L, Braunschweig R, Coindre JM, Benhattar J. 2002. The human telomerase RNA gene (hTERC) is regulated during carcinogenesis but is not dependent on DNA methylation. Carcinogenesis 23:2025-2030.
13. Henson JD, Neumann AA, Yeager TR, Reddel RR. 2002. Alternative lengthening of telomeres in mammalian cells. Oncogene 21:598-610.
14. Huang HY, Illei PB, Zhao Z, Mazumdar M, Healey JH, Huvos AG, Wexler LH, Gorlick R, Meyers PA, Ladanyi M. 2004. Ewing sarcomas with p53 mutations or p16/p14ARF homozygous deletions: a highly aggressive subset associated with poor chemoresponse. J Clin Oncol (in press).
15. Jhanwar SC, Elahi A, Cote R, Chen Q, Lewis R, Huvos AG, Healey JH, Ladanyi M. 1993. Establishment and characterization of a Ewing's sarcoma cell line with p53 mutation and MDM2 gene amplification. Proc Am Assoc Cancer Res 34:500.
16. Karlseder J, Smogorzewska A, de Lange T. 2002. Senescence induced by altered telomere state, not telomere loss. Science 295: 2446-2449.
17. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. 1994. Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015.
18. Kim SH, Kaminker P, Campisi J. 2002. Telomeres, aging and cancer: in search of a happy ending. Oncogene 21:503-511.
19. Ladanyi M. 2002. EWS-FLI1 and Ewing's sarcoma: recent molecular data and new insights. Cancer Biol & Therap 1:330-336.
20. Lee KH, Rudolph KL, Ju YJ, Greenberg RA, Cannizzaro L, Chin L, Weiler SR, DePinho RA. 2001. Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Proc Natl Acad Sci USA 98:3381-3386.
21. Maser RS, DePinho RA. 2002. Connecting chromosomes, crisis, and cancer. Science 297:565-569.
22. Masutomi K, Yu EY, Khurts S, Ben Porath I, Currier JL, Metz GB, Brooks MW, Kaneko S, Murakami S, DeCaprio JA, Weinberg RA, Stewart SA, Hahn WC. 2003. Telomerase maintains telomere structure in normal human cells. Cell 114:241-253.
23. Matthews P, Jones CJ, Skinner J, Haughton M, de Micco C, Wynford-Thomas D. 2001. Telomerase activity and telomere length in thyroid neoplasia: biological and clinical implications. J Pathol 194:183-193.
24. Mitelman F. 2000. Recurrent chromosome aberrations in cancer. Mutat Res 462:247-253.
25. Montgomery E, Argani P, Fisher C, Kern SE, Lengauer C. 2003. Analysis of anaphase figures in routine histologic sections distinguishes chromosomally unstable type sarcomas from types with characteristic translocations. Mod Pathol 16:17A.
26. Montgomery E, Argani P, Hicks JL, DeMarzo AM, Meeker AK. 2004. Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. Am J Pathol 164: 1523-1529.
27. Ohali A, Avigad S, Cohen IJ, Meller I, Kollender Y, Issakov J, Gelernter I, Goshen Y, Yaniv I, Zaizov R. 2003. Association between telomerase activity and outcome in patients with nonmetastatic Ewing family of tumors. J Clin Oncol 21:3836-3843.
28. Scheel C, Poremba C. 2002. Telomere lengthening in telomerase-negative cells: the ends are coming together. Virchows Arch 440: 573-582.
29. Scheel C, Schaefer KL, Jauch A, Keller M, Wai D, Brinkschmidt C, van Valen F, Boecker W, Dockhorn-Dworniczak B, Poremba C. 2001. Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas. Oncogene 20:3835-3844.
30. Schneider-Stock R, Boltze C, Jager V, Epplen J, Landt O, Peters B, Rys J, Roessner A. 2003. Elevated telomerase activity, c-MYC-, and hTERT mRNA expression: association with tumour progression in malignant lipomatous tumours. J Pathol 199:517-525.
31. Seger YR, Garci, Cao M, Piccinin S, Cunsolo CL, Doglioni C, Blasco MA, Hannon GJ, Maestro R. 2002. Transformation of normal human cells in the absence of telomerase activation. Cancer Cell 2:401-413.
32. Shay JW, Bacchetti S. 1997. A survey of telomerase activity in human cancer. Eur J Cancer 33:787-791.
33. Sorensen PHB, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. 1994. A second Ewing's sarcoma translocation, t(21; 22), fuses the EWS gene to another ets-family transcription factor, ERG. Nat Genet 6:146-151.
34. Takahashi A, Higashino F, Aoyagi M, Yoshida K, Itoh M, Kyo S, Ohno T, Taira T, Ariga H, Nakajima K, Hatta M, Kobayashi M, Sano H, Kohgo T, Shindoh M. 2003. EWS/ETS fusions activate telomerase in Ewing's tumors. Cancer Res 63:8338-8344.
35. Ulaner GA. 2004. Telomere maintenance in clinical medicine: beginning to understand chromosome ends. Am J Med (in press).
36. Ulaner GA, Huang HY, Otero J, Zhao Z, Ben Porat L, Satagopan JM, Gorlick R, Meyers P, Healey JH, Huvos AG, Hoffman AR, Ladanyi M. 2003. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 63:1759-1763.
37. Wong KK, Chang S, Weiler SR, Ganesan S, Chaudhuri J, Zhu C, Artandi SE, Rudolph KL, Gottlieb GJ, Chin L, Alt FW, DePinho RA. 2000. Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. Nat Genet 26:85-88.
38. Wu G, Jiang X, Lee WH, Chen PL. 2003. Assembly of functional ALT-associated promyelocytic leukemia bodies requires Nijmegen Breakage Syndrome 1. Cancer Res 63:2589-2595.
39. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Ling ner J, Dalla-Favera R. 1999. Direct activation of TERT transcription by c-MYC. Nat Genet 21:220-224.
40. Wynford-Thomas D. 1997. Proliferative lifespan checkpoints: cell-type specificity and influence on tumour biology. Eur J Cancer 33:716-726.
41. Yan P, Benhattar J, Coindre JM, Guillou L. 2002. Telomerase activity and hTERT mRNA expression can be heterogeneous and does not correlate with telomere length in soft tissue sarcomas. Int J Cancer 98:851-856.
42. Zucman J, Melot T, Desmaze C, Ghysdael J, Plougastel B, Peter M, Zucker JM, Triche TJ, Sheer D, Turc-Carel C, Ambros P, Combaret V, Lenoir G, Aurias A, Thomas G, Delattre O. 1993. Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J 12:4481-4487.